NFE2L2 and diabetic cardiomyopathy: Then we summarized three main signaling pathways that currently trigger diabetic cardiomyopathy (Figure 2): 1) TLR4/NF-kB Inflammasome/NLRP3 Inflammasome Signaling Pathway; 2) AMPK/ROS/TXNIP/NLRP3 Inflammasome Signaling Pathway; and 3) AMPK/SIRT1/Nrf2/HO-1/NF-kB Inflammasome Signaling Pathway, which can be used to design DCM-related drugs through the above signaling pathways in the future.